Methods for treating attention deficit disorder
AssigneeFabre Kramer Pharmaceutical, Inc.
InventorsStephen J. Kramer, Louis F. Fabre
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treatment of attention deficit disorder by administering certain 5-HT1A receptor agonists
Claims51
A method of treating attention deficit disorder, or symptoms thereof, in a patient in need thereof comprising administering a therapeutically effective amount of an azapirone, or a pharmaceutically acceptable salt thereof, wherein the azapirone has no dopamine receptor activity.
A method of treating attention deficit disorder, or symptoms thereof, in a patient in need thereof comprising administering a therapeutically effective amount of an adamantyl aryl piperazinyl carboxamide or heteroaryl piperazinyl carboxamide 5-HT1A receptor agonist, or a pharmaceutically acceptable salt thereof.
A method of treating attention deficit disorder, or symptoms thereof, in a patient in need thereof comprising administering a therapeutically effective amount of a hetrobicyclic-aryl-piperazine 5-HT1A receptor agonist, or a pharmaceutically acceptable salt thereof.
A method of treating attention deficit disorder, or symptoms thereof, in a patient in need thereof comprising administering a therapeutically effective amount of two or more compounds selected from the group consisting of geprione, ipsapirone, tandospirone, flesinoxan, and adatanserin.
Dependencies are inferred from the claim text.